| Literature DB >> 35931735 |
Kangjin Kim1, Sanghun Lee2, Sang-Chul Park3, Nam-Eun Kim1, Chol Shin4,5, Seung Ku Lee5, Youngae Jung6, Dankyu Yoon7, Hyeonjeong Kim8, Sanghyun Kim8, Geum-Sook Hwang9, Sungho Won10,11,12.
Abstract
Recent investigations have revealed that the human microbiome plays an essential role in the occurrence of type 2 diabetes (T2D). However, despite the importance of understanding the involvement of the microbiota throughout the body in T2D, most studies have focused specifically on the intestinal microbiota. Extracellular vesicles (EVs) have been recently found to provide important evidence regarding the mechanisms of T2D pathogenesis, as they act as key messengers between intestinal microorganisms and the host. Herein, we explored microorganisms potentially associated with T2D by tracking changes in microbiota-derived EVs from patient urine samples collected three times over four years. Mendelian randomization analysis was conducted to evaluate the causal relationships among microbial organisms, metabolites, and clinical measurements to provide a comprehensive view of how microbiota can influence T2D. We also analyzed EV-derived metagenomic (N = 393), clinical (N = 5032), genomic (N = 8842), and metabolite (N = 574) data from a prospective longitudinal Korean community-based cohort. Our data revealed that GU174097_g, an unclassified Lachnospiraceae, was associated with T2D (β = -189.13; p = 0.00006), and it was associated with the ketone bodies acetoacetate and 3-hydroxybutyrate (r = -0.0938 and -0.0829, respectively; p = 0.0022 and 0.0069, respectively). Furthermore, a causal relationship was identified between acetoacetate and HbA1c levels (β = 0.0002; p = 0.0154). GU174097_g reduced ketone body levels, thus decreasing HbA1c levels and the risk of T2D. Taken together, our findings indicate that GU174097_g may lower the risk of T2D by reducing ketone body levels.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35931735 PMCID: PMC9440228 DOI: 10.1038/s12276-022-00816-x
Source DB: PubMed Journal: Exp Mol Med ISSN: 1226-3613 Impact factor: 12.153
Fig. 1Summary chart of data analysis.
Datasets and analyses employed in the current study are described. Sample sizes for each analysis are presented.
Fig. 2Taxonomic composition at the phylum level for phases 1, 2, and 3.
Profile plots for phases 1 (a), 2 (b), and 3 c showing the relative abundances of bacterial taxa at the phylum level for each individual are presented.
Analysis of the associations between type 2 diabetes (T2D) and bacterial genera.
| Phenotype | Genus | Estimate | Std Err | DF | FDR | |
|---|---|---|---|---|---|---|
| −189.13 | 46.63 | 735 | 0.00006 | 0.00393 | ||
| −13.07 | 5.31 | 735 | 0.01411 | 0.38195 | ||
| −3.49 | 1.43 | 735 | 0.01489 | 0.38195 | ||
| −86.44 | 37.49 | 735 | 0.02140 | 0.38195 | ||
| −25.38 | 11.70 | 735 | 0.03039 | 0.38195 | ||
| −48.29 | 22.95 | 735 | 0.03568 | 0.38195 | ||
| 6.71 | 3.21 | 735 | 0.03669 | 0.38195 | ||
| −71.10 | 34.46 | 735 | 0.03944 | 0.38195 | ||
| −65.20 | 32.53 | 735 | 0.04538 | 0.38195 | ||
| 7.74 | 3.91 | 735 | 0.04842 | 0.38195 |
Associations between genera and T2D-at-risk/T2D and Binary_T2D were tested, and significant associations at a significance level of 0.05 are summarized.
Fig. 3Relative proportions of GU174097_g in different type 2 diabetes (T2D) groups.
The mean relative proportions of GU174097_g are provided for the Healthy in Phases 1-3, T2D in Phases 1-3, Healthy to T2D-at-risk/T2D, and T2D-at-risk/T2D to Healthy groups and are compared according to the T2D status. The Healthy in Phases 1-3 group included subjects who were healthy in phases 1, 2, and 3. The T2D in Phases 1-3 group included subjects who had T2D in phases 1, 2, and 3. The Healthy to T2D-at-risk/T2D group included subjects who were healthy in phase 1 and became T2D patients or T2D-at-risk in phase 3. The T2D-at-risk/T2D to Healthy group included subjects who were T2D-at-risk/T2D in phase 1 and healthy in phase 3. The p values were calculated based on simple linear regression using the log relative proportion of GU174097_g as a response variable and phase variable. The relative proportion of GU174097_g was log-transformed after adding one to avoid zero values. The phase variable is coded by 1, 2, and 3 for phases 1, 2, and 3, respectively.
Analysis of the associations between diabetes risk indicators and GU174097_g.
| Phenotype | rssho | FDR | |
|---|---|---|---|
| Ins60 | 0.0950 | 0.0018 | 0.0026 |
| HbA1c | −0.0434 | 0.1548 | 0.1872 |
| Glu0 | 0.0306 | 0.3165 | 0.3647 |
| Ins0 | −0.0301 | 0.3236 | 0.3721 |
| HOMA-IR | −0.0270 | 0.3756 | 0.4255 |
| Glu60 | −0.0229 | 0.4536 | 0.5045 |
| Ins120 | 0.0177 | 0.5622 | 0.6096 |
| Glu120 | 0.0072 | 0.8138 | 0.8424 |
| BMI | −0.0070 | 0.8186 | 0.8469 |
Associations between diabetes risk indicators and GU174097_g were tested and are presented.
Analysis of the associations between GU174097_g and ketone bodies.
| Phenotype | rho | |
|---|---|---|
| Acetoacetate | −0.0938 | 0.0022 |
| 3-hydroxybutyrate | −0.0829 | 0.0069 |
Associations between the ketone bodies acetoacetate and 3-hydroxybutyrate and GU174097_g were tested and are presented.